Evaluating the Efficacy and Safety of Erythromycin for the Treatment of Gastroparesis in Infants and Children. Chang, Eugenie (E);Harkin, Maura (M);Miller, Jamie L (JL);Walsh, Christina (C);Neely, Stephen B (SB);Johnson, Peter N (PN); |
Author information J Pediatr Pharmacol Ther.2025 Feb 10;30(1):70-77.doi:10.5863/1551-6776-30.1.70 Abstract OBJECTIVES: Erythromycin has been utilized for gastroparesis and feeding intolerance in adults and neonates, but limited studies exist for infants and children. The purpose of this study was to evaluate the safety and efficacy of erythromycin for gastroparesis in pediatric patients. The primary objective was to identify the number of patients with gastroparesis improvement, defined as no additional use of promotility agents, no erythromycin dose increases or need for other interventions (transpyloric or gastrostomy-jejunostomy tube). Secondary objectives included comparisons of clinical characteristics and outcomes between those with and without gastroparesis improvement and identification of patients with QTc prolongation following erythromycin initiation (QTc interval >450 ms or ≥25% increase from baseline). |
© Copyright 2013-2025 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only.
Use of this website is governed by the GIHF terms of use and privacy statement.